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ABSTRACT
Transplant-associated microangiopathy (TAM) is a life-threatening complication after allogeneic HSCT,
particularly with the use of calcineurin inhibitors as post-transplantation immunosuppressive therapy. We
report our experience with TAM after HSCT with tacrolimus-based GVHD prophylaxis in a single-center
study. Sixty-six of 1219 transplant recipients developed TAM with a cumulative incidence of 5.9%. Risk factors
for TAM were female gender, lymphoid malignancy, receipt of a matched unrelated donor, and grade II-IV
aGVHD. Most patients had infection and/or active GVHD at the diagnosis of TAM (82%). In the absence of
renal dysfunction or encephalopathy, tacrolimus was generally continued, maintaining blood levels within the
lower therapeutic range. Sixty-three patients were treated with plasma exchange. The cumulative incidence
of response of TAM was 60%. Only 1 patient had a response of TAM without resolution of concomitant
infections or GVHD. Six-month survivals were 0% and 50% for TAM nonresponders and responders,
respectively. In conclusion, TAM is a common, life-threatening complication of allogeneic hematopoietic
transplantation using tacrolimus prophylaxis. Control of TAM generally requires response of associated
infections and GVHD. TMA response may occur despite continuation of tacrolimus treatment.
© 2007 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Transplant-associated microangiopathy (TAM) is
ne of the most serious complications after allogeneic
SCT [1]. Clinical manifestations include severe
hrombocytopenia, microangiopathic hemolysis, and
requently renal dysfunction and neurologic compli-
ations. The reported incidence of TAM after HSCT
aries from 0.5% to 70%, indicating the inconsisten-
ies in the criteria for diagnosis in the literature and
ariability in patient, disease, and treatment charac-
eristics of the study groups [2-4].
Diffuse endothelial cell injury; tissue factor ex-
ression, exposure of the thrombogenic subendothe- (ial matrix, and in turn platelet activation and aggre-
ation are considered the basis of the pathophysiology
f TAM [5-8]. Transplantation from an unrelated or
ismatched donor, use of calcineurin inhibitors, and
he presence of infection and GVHD have been re-
orted as risk factors for development of TAM after
llogeneic HSCT [3,9-12].
There is no consensus for treatment of post-trans-
lantation TAM. In contrast to idiopathic thrombotic
hrombocytopenic purpura, TAM is not associated
ith a marked decrease in ADAMTS13 (von Wille-
rand factor cleaving protease) level or its inhibitors
13-15]. The efﬁcacy of therapeutic plasma exchange
PE) has not been established for TAM. Cyclosporine-
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B. Oran et al.470nduced TAM may respond to dose reduction or dis-
ontinuation [9,16], but the literature for management
f tacrolimus-induced TAM is less informative. TAM
emains a life-threatening complication after alloge-
eic HSCT [1,2].
We report the risk factors for development of
AM after allogeneic HSCT for hematologic malig-
ancies with tacrolimus-based GVHD prophylaxis
nd the factors associated with a favorable treatment
esponse with therapeutic PE.
ETHODS
atient Eligibility and Data Collection
All adult patients receiving ﬁrst allogeneic BMT
r blood progenitor cell transplantation as treatment
or hematologic malignancies and myelodysplastic
yndrome at the University of Texas/MD Anderson
ancer Center from January 1, 1998 through Decem-
er 31, 2004 were reviewed. In the analysis were
ncluded 1219 consecutive patients who had engraft-
ent after non-T cell-depleted transplantation and
acrolimus-based GVHD prophylaxis. Retrospective
hart review was reviewed and approved by the MD
nderson Cancer Center institutional review board.
ata on patient, donor, and disease characteristics,
reatment, and outcomes of transplantation were col-
ected.
onditioning Regimens and GVHD Prophylaxis
Different preparative regimens were used. We
rouped preparative regimens as myeloablative and
educed intensity conditioning (RIC) using the crite-
ia of the Center for International Blood and Marrow
ransplantation Research. Five hundred seventy-one
atients (46.8%) were treated with ablative regimens
hat primarily included busulfan and cyclophospha-
ide (n  193), cyclophosphamide and 10 Gy TBI
n  152), ﬂudarabine and high-dose busulfan (n 
19), and carmustine, etoposide, cytarabine, and mel-
halan (n  67). Six hundred forty-eight patients
53.3%) received RIC mostly including ﬂudarabine
nd melphalan (n  239) or ﬂudarabine and busulfan
ith a busulfan dose 12 mg/kg (n  94) or ﬂudara-
ine/cyclophosphamide with or without rituximab
n  193).
Donor BM or blood progenitor cells were pro-
ured using standard mobilization and harvesting
echniques. These were infused i.v. on day 0. For ABO
ncompatible BM transplants, erythrocytes or plasma
ere depleted as indicated to prevent hemolysis. BM
r PB progenitor cells procured from unrelated do-
ors were obtained through National Marrow Donor
rogram.
The transplant was from an HLA-identical related
onor in 662 cases (54.3%) and from an unrelated “onor in 448 cases (36.8%). At least 1 antigen mis-
atched related and unrelated donor, by serologic
lass I and high-resolution molecular DRB1 typing,
as used in 77 (6.3%) and 32 (2.6%) cases, respec-
ively. The cell source was BM in 594 (48.7%), PB
rogenitor cells in 602 (49.4%), and cord blood in 23
1.9%).
GVHD prophylaxis was tacrolimus based in all
atients; 1197 patients (98.2%) received methotrexate
mg/m2 i.v. on days 1, 3, 6, and, in some patients, 11
fter transplantation. ATG was given to 299 patients
24.5%), primarily those receiving HLA nonidentical
r unrelated donor transplants. Tacrolimus was
tarted on day 2 and dosing was adjusted to main-
ain blood levels of 5 to 15 ng/dL during the ﬁrst 3
o 6 mo and then tapered depending on the protocol
nd the presence or absence of GVHD. No patients
eceived sirolimus or T cell depletion for GVHD
rophylaxis.
efinitions
Our deﬁnition of TAM was based on the recent
iagnostic criteria proposed by an international work-
ng group [17]. The diagnosis of TAM after allogeneic
SCT required fulﬁllment of the following criteria:
a) schistocytosis 1 per high-power ﬁeld on blood
mear ﬁlm; (b) de novo, prolonged, or progressive
hrombocytopenia (platelet count 50 000 or 50%
ecrease from baseline values); (c) sudden or persistent
ncrease50% in lactate dehydrogenase (LDH) com-
ared with baseline value; (d) decrease in hemoglobin
oncentration or increased RBC transfusion require-
ent; (e) if available, decrease in serum haptoglobin
evel; (f) negative Coombs test results; and (g) normal
rothrombin time and activated partial thromboplas-
in time.
Response to therapy for TAM required fulﬁllment
f the following criteria: (a) none or only occasional
chistocytes per high-power ﬁeld on blood smear ﬁlm;
b) 50% decrease in LDH, which was sustained for
7 d without PE; (c) no evidence of ongoing hemo-
ysis, including normal indirect bilirubin and serum
aptoglobin levels when available; and (d) resolution
f nonfocal neurologic symptoms.
The indication for transplantation was categorized
s myeloid malignancies including AML, myelodys-
lastic syndrome, and CML, or lymphoid malignan-
ies including ALL, CLL, multiple myeloma, and
ymphomas. Disease status at allogeneic HSCT was
eﬁned according to the following criteria: “good-
isk” disease status included acute leukemias with mar-
ow aspirate containing 5% blasts and recovering
B counts, CML in chronic phase, multiple myeloma,
nd lymphomas in remission. Other patients with
ore advanced diseases were considered to have
poor-risk” disease status.
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TAM after Allogeneic SCT 471Day 0 was the stem cell infusion day. The diag-
osis of acute and chronic GVHD was based on con-
ensus criteria [18,19]. Status of GVHD at time of
AM diagnosis was categorized as no, quiescent, or
ctive GVHD. GVHD was considered “quiescent” if
he clinical manifestations had resolved with treat-
ent and the immunosuppressive treatment was being
apered.
CMV infection/reactivation was deﬁned as a pos-
tive culture or pp65 antigenemia assay based on 1
p65 cell/106 neutrophils assessed. Invasive fungal
nfection required evidence of infection by biopsy or
he isolation of fungus from typically sterile speci-
ens. Based on these deﬁnitions, infectious diseases at
AM were categorized as (a) isolated CMV infection,
b) fungal infection with or without viral or bacterial
nfections, or (c) viral and/or bacterial infections. In-
ections that were diagnosed within the 14 d before
iagnosis of TAM and were active at the diagnosis of
AM were included.
anagement of TAM
Tacrolimus was generally continued with dose
djustment into the lower therapeutic range (5-10
g/mL) and was permanently discontinued only for
rogressive renal failure or encephalopathy. Corti-
osteroids were used for treatment of GVHD and
ere routinely initiated or increased for prevention of
VHD if tacrolimus was discontinued. Concomitant
nfections were treated with antimicrobial therapy
ased on results of culture and sensitivity testing.
Therapeutic PE was performed using a Cobe
pectra cell separator (Gambro BCT, Lakewood, Co).
atients provided written informed consent for the
rocedure. One time to 1.5 times the plasma volume
as exchanged with a mixture of albumin with fresh
rozen plasma or cryosupernatant plasma. PE was
ontinued until a clinical response was documented or
atients’ clinical condition deteriorated such that they
ere considered to have treatment failure. The fre-
uency of PE was typically daily at the beginning and
itrated as needed to control disease manifestations to
everal times weekly and then once weekly depending
n response. PE was discontinued when criteria for
esponse were achieved without exacerbation between
pheresis sessions. Platelet transfusions were adminis-
ered when the platelet count was 20  109/L or in
he presence of major bleeding.
tatistical Methods
The cumulative incidence of TAM and response
o PE were analyzed as death without TAM and death
ithout response to therapy as competing risks, re-
pectively [20]. Risk factors for TAM development
nd predictors of response to TAM were evaluated
sing Cox proportional hazards model. Risk factors lnalyzed for TAM included patient’s age (as quartiles),
ender, disease diagnosis (myeloid versus lymphoid),
onor type (matched related donor, matched unre-
ated donor, mismatched related donor, mismatch un-
elated donor), disease status at HSCT (good risk
ersus poor risk disease status), use of TBI in the
reparative regimen, intensity of preparative regimen
myeloablative versus RIC), stem cell source (BM,
lood pressure, cord blood), and occurrence of grade
I-IV aGVHD as a time-dependent variable. Patients
ho received a second allogeneic HSC transplant had
ollow-up time censored at the time of second stem
ell infusion. Predictive factors for response included
isease characteristics of TAM including renal dys-
unction, neurologic dysfunction, GVHD (none, qui-
scent, active), infection (isolated CMV infection, fun-
al infection with or without bacterial and/or viral
nfections, bacterial and/or viral infection), and obser-
ation of supratherapeutic blood levels of tacrolimus.
n Cox proportional hazards models, variables that
ere signiﬁcant at the .1 level on univariate analysis or
ere considered to be clinically signiﬁcant were eval-
ated in a multivariate analysis. For response evalua-
ion, only patients with their ﬁrst episode of TAM
ere included. Overall survival was estimated by
aplan-Meier curves and comparisons were pre-
ormed by log-rank test. Comparisons of pre- and
ost-TAM tacrolimus levels were performed using
ilcoxon tests. Statistical signiﬁcance was determined
t the .05 level. All P values were 2-sided. Statistical
nalysis was performed using STATA 7.0, SAS 9.1
SAS Institute Inc., Cary, NC), and S-plus 6.0.
ESULTS
ncidence and Time of Onset of TAM
Median follow-up time for surviving patients was
7.4 mo after SCT (range, 1.2-88 mo). Sixty-six of
219 patients developed TAM, with a cumulative in-
idence of 5.9%. Median interval from transplantation
o TAM was 67 d (range, 11 d-5 yr), with only 4
atients presenting after a year after transplantation.
nset of TAM was within 100 d after transplantation
n 45 patients (68.2%) and after day 100 in 21.
isk Factors for Development of TAM
Patient characteristics and their association with
AM are presented in Table 1. On univariate analysis,
igniﬁcant risk factors associated with development of
AM were gender, donor type, and aGVHD grade
I-IV. Cumulative incidences of TAM with each of
he risk factors are summarized in Figures 1-3. In
ultivariate analysis by Cox proportional hazards
odel, results were similar to those obtained in uni-
ariate analysis with the exception that the effect of
ymphoid malignancy diagnosis, which was marginally
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B. Oran et al.472igniﬁcant in univariate analysis (hazard ratio, 1.55;
 .08), became signiﬁcant (hazard ratio, 1.75; P 
03; Table 2). Patient age, disease status, and intensity
f preparative regimens were not associated with the
isk of TAM in this study.
linical Features at Diagnosis of TAM
Of the 66 patients who developed TAM, 3 had 2
pisodes. The clinical features of the 69 TAM epi-
able 1. Patient Characteristics and Their Association with TAM by U
No. of Patients (%
ge (yr)
<47 621 (50.9)
>47 598 (49.1)
ender
Male 739 (60.6)
Female 480 (39.4)
iagnosis
Myeloid malignancy 638 (52.3)
Lymphoid malignancy 581 (47.7)
isease status
Good risk 451 (37)
Poor risk 768 (63)
onor type
Matched related donor 662 (54.3)
Matched unrelated donor 448 (36.8)
Mismatched related donor 77 (6.3)
Mismatched unrelated donor 33 (2.6)
reparative regimen
Reduced intensity 648 (53.2)
Myeloablative 571 (46.8)
BI in preparative regimen
No 1044 (85.6)
Yes 175 (14.4)
GVHD II-IV*
R indicates hazard ratio; CI, conﬁdence interval.
Time-dependent variable.
igure 1. Cumulative incidences of TAM were 7.7% for female
atients and 3.7% for male patients (P  .003). modes are summarized in Table 3. Median platelet
ount at diagnosis of TAM was 19  109/L (range,
-47). In 35 episodes (50.7%), patients had de novo
hrombocytopenia; in 34 episodes (49.3%), sus-
ained thrombocytopenia was observed. Median
DH level was 2807 IU/L (upper limit of normal is
18 IU/L) and the median difference compared
ith baseline levels was 1785 IU/L (range, 578-
te Cox Proportional Hazards Models
HR 95% CI P
1.00
1.37 0.84-2.22 0.21
1.00
2.03 1.25-3.31 0.004
1.00
1.55 0.95-2.55 0.08
1.00
1.32 0.79-2.20 0.30
1.00
3.04 1.81-5.12 <0.001
1.97 0.68-5.68 0.21
2.41 0.56-10.36 0.24
1.00
1.02 0.63-1.66 0.93
1.00
1.56 0.85-2.86 0.15
4.47 2.76-7.24 <0.001
igure 2. Cumulative incidences of TAM were 6.5% for patients
ith lymphoid malignancies and 4.2% for patients with myeloidnivaria
)alignancies (P  .03).
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TAM after Allogeneic SCT 473400 IU/L). Serum haptoglobin levels were avail-
ble in 63 episodes and all were lower than our
aboratory’s maximum normal level of 30 mg/dL,
nd in 59 of 63 episodes it was 6 mg/dL. More
han a 50% increase in serum total bilirubin was
ocumented in 46 episodes (66.7%). An increase in
ndirect bilirubin could not be analyzed because
nly 10 patients had baseline levels available.
In 46 episodes (66.6%), patients were documented
o have an active infection at the time of TAM diag-
osis. Ten patients had isolated CMV, 22 had bacte-
ial and/or other viral infection, and 14 had fungal
nfections. Two more patients were diagnosed with
ungal infections during the course of TAM.
Renal function abnormality deﬁned as 50% in-
rease of baseline serum creatinine level occurred in
2 patients (32%) and neurologic dysfunction was
bserved in 28 cases (40%), respectively. The most
ommon presentation of CNS involvement was men-
al status changes and/or headache.
Hypertension was common; systolic blood pres-
ure140 mmHg was seen in 66 episodes (95%) with
median of 165 (range, 140-202) and diastolic blood
ressure was 85 mm Hg in 57 episodes (83%) with
median of 100 (range, 85-120) at least once during
he disease course despite appropriate treatment. He-
odialysis was required for renal failure in 22 episodes
igure 3. Compared with mismatched unrelated donor (MUD),
umulative incidence of TAM was lower for matched related donor
MRD) during the ﬁrst 100 d after transplantation; this excessive
ncidence with MUD was also evident after day 100. Cumulative
ncidences of TAMwere 3.1% for MRD, 8.4% for MUD, and 5.3%
or mismatched related donor (MMRD; P  .001). Cumulative
ncidence of TAM for MMUD was not analyzed because of a small
ample with few events.32%) during the course of TAM. *mmunosuppressive Therapy
Patients were receiving systemic corticosteroid
reatment in 62 of 69 episodes (90%) at the time of
iagnosis of TAM; 29 for active GVHD, 24 for qui-
scent GVHD, and 9 for other reasons. In 35 episodes
56%), the methylprednisolone dose was 1 mg/kg
aily. Two of 7 patients who were not receiving cor-
icosteroids initiated methylprednisolone treatment
fter diagnosis of TAM, concomitant with the dose
eduction of tacrolimus.
In 65 episodes, patients were on tacrolimus treat-
ent with a median trough blood level of 9.3 ng/dL
range, 3-24 ng//dL) at the time of diagnosis of TAM.
he highest tacrolimus blood level at or within the
eek before TAM was 15 ng/dL in 26 patients
39.4%). Upon diagnosis of TAM, tacrolimus was
emporarily discontinued in 12 (18.5%), switched to
yclosporine in 3 (4.6%), and its dose was reduced in
9 episodes (44.6%). Tacrolimus dosing was adjusted
o produce trough levels in the lower portion of the
herapeutic range (5-10 ng/mL). The most common
easons for discontinuation were worsening renal
unction and neurologic manifestations. There was no
ifference of median and highest trough tacrolimus
evels at TAM among cases that tacrolimus was dis-
ontinued or continued. Supratherapeutic levels were
anaged primarily by dose reduction. Glucocorti-
oids were routinely initiated or increased for preven-
ion of GVHD if tacrolimus was discontinued.
lasma Exchange
Sixty-six of 69 episodes (95.7%) were treated with
E with a median number of 10 (range, 2-33). In the
emaining 3 episodes, patients were considered too
nstable to tolerate the procedure. Fourteen compli-
ations possibly related to PE were observed in 12
AM episodes (14.5%), including blood pressure
hanges (hypertension, n  3; hypotension, n  4),
ypoxia (n 2), seizures in the setting of hypertension
n  3), and volume overload (n  1). One patient
1.3%) had an intracranial hemorrhage.
isease Course and Response to Treatment
ith PE
A response of TAM, as deﬁned above, was ob-
erved in 38 of 66 episodes in patients who received
able 2. Results of Multivariable Cox Proportional Hazards Models
Variables HR 95% CI P
emale 2.09 1.29-3.41 0.003
ymphoid malignancy 1.75 1.07-2.87 0.03
UD 2.41 1.48-3.94 <0.001
GVHD* 4.33 2.63-7.15 <0.001
R indicates hazard ratio; CI, conﬁdence interval; MUD, matched
unrelated donor.Time-dependent variable.
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B. Oran et al.474E with a cumulative incidence of response of 60%.
ypertension usually responded promptly. Median
ime to response was 29 d. We analyzed the associa-
ion between response and baseline disease character-
stics for the ﬁrst TAM episodes in 63 patients who
ere treated with PE. Only presence of fungal infec-
ion was found to be negatively associated with re-
ponse on univariate analysis (hazard ratio, 0.3; 95%
onﬁdence interval, 0.1-0.9; P  .03; Figure 4). Re-
ponse of TAM was related to control of GVHD and
ctive infections (Table 4). No response of TAM was
ocumented in the absence of response of underlying
nfections and likewise all but 1 response was observed
n patients whose GVHD was controlled with appro-
riate treatment. The approach to tacrolimus treat-
ent (discontinuation, dose reduction, or no change)
n patients with therapeutic blood levels was found to
ave no affect on TAM response.
urvival and Cause of Death
Fifty-ﬁve of 66 patients with TAM died at a me-
ian of 3 mo from the date of the ﬁrst episode. Median
able 3. Clinical Features of TAM Episodes at Diagnosis
Variables
Baseline Values before On
No. Median 25%
latelet count (109/L) 69 42
emoglobin (g/dL) 69 9.1
DH (IU/L) 69 964
reatinine (mg/dL) 69 1.1
otal bilirubin (mg/dL) 69 0.7
ndirect bilirubin (mg/dL) 10 0.7
igure 4. Cumulative incidence of response to TAM was similar for
atients with no infection, isolated CMV, and bacterial and/or other
iral infections (72%, 70%, and 70%, respectively). Patients with
ungal infection had a lower cumulative incidence of response
20%).urvivals from the date of the ﬁrst episode for nonre-
ponders and responders were 1.07 and 7.5 mo, re-
pectively (P  .0001). Survivals at 6 months were 0%
nd 50.7% for TAM nonresponders and responders,
espectively (Figure 5). Despite control of the clinical
anifestations in TAM responders, there was a high
ate of mortality related to acute or chronic GVHD
with or without complicating infections; Table 5).
our patients with no response of TAM died of hem-
rrhage, 2 with intracranial bleeding and 2 with dif-
use alveolar hemorrhage. One patient with response
o therapy died of intracranial bleeding 1 mo after
esolution of TAM.
ISCUSSION
TAM after transplantation is life-threatening
omplication of allogeneic SCT. TAM is a complex
yndrome that may result from multiple precipitating
actors [2]. In this retrospective, single-center cohort
f 1219 patients, we used stringent diagnostic criteria
ased on a consensus formed by an international
orking group [19]. We included only patients with
acrolimus-based GVHD prophylaxis. Cyclosporine is
ell established as cytotoxic to endothelial cells in
itro and in vivo, and cyclosporine may cause TAM
AM Values at TAM Diagnosis
ercentile No. Median 25%-75% Percentile
8 69 19 15-25
0.2 69 8.5 7.8-9.3
331 69 2807 2329-4514
.5 69 1.4 1.1-1.9
.0 69 1.6 1.1-2.6
.1 51 1.1 0.7-1.5
able 4. TAM Response Related to Response of Coexisting Infection
r GVHD
Response to
Appropriate
Treatment
TAM
Response
No. % No. %
nfection at TAM
No infection NA NA 14/20 70
CMV infection* 10/10 100 7/10 70
Bacterial and/or viral infection† 15/21 71.4 13/21 61.9
Fungal infection 4/15 26.6 4/15 26.6
VHD status at TAM
None NA NA 10/15 66.73
Quiescent NA NA 18/24 75
Active 11/27 40.7 10/27 37
A indicates not applicable.
Included patients with isolated CMV infection.
Includes patients with infections other than isolated CMV andset of T
-75% P
23-9
8.4-1
699-1
0.9-1
0.1-1fungal infection.
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TAM after Allogeneic SCT 475ven without other regimen-related toxicity and/or
VHD [16,21]. The literature of TAM associated
ith tacrolimus treatment is not as well established.
he cumulative incidence of TAM was 5.9% in this
tudy. The question of whether TAM is more or less
requent with tacrolimus compared with cyclosporine
equires direct comparison of these agents in compa-
able patient groups using uniform diagnostic criteria.
In this study, the major risk factors for develop-
ent of TAM were female sex, diagnosis of a lym-
hoid malignancy, receipt of an unrelated donor
ransplant, and development of aGVHD. Patients re-
eiving unrelated donor or mismatched transplants
eceived ATG in the preparative regimen; it is not
ossible to assess whether treatment with ATGn
as independently associated with TAM. The in-
reased risk of TAM with female gender has been
eported in the nontransplantation [22,23] and
ransplantation [9,10,24] settings. To our knowl-
dge, increased risk with a lymphoid malignancy has
ot been reported. Although the explanation is un-
nown, these patients were heavily pretreated, and
umulative exposure to chemotherapy and radiation
ight play a role.
igure 5. Overall survival after TAM diagnosis was signiﬁcantly sh
median overall survival, 1 and 7.5 mo, respectively; P  .001).
able 5. Causes of Death after TAM by Response to Therapy
Cause of Death Responders (%) Nonresponders (%)
GVHD 3 (11.1) 13 (46.4)
GVHD 9 (33.3) 4 (14.3)
nfection 1 (3.7) 4 (14.3)
rogression of malignancy 8 (29.7) 1 (3.5)
emorrhage 1 (3.7) 4 (14.3)
ther 5 (18.5) 2 (7.2)t
otal 27 28GVHD is an established risk factor for TAM
1,9,24,25]. An association between inﬂammatory cyto-
ines and thrombosis has been suggested. [26] A recent
tudy reported that IL-8 and TNF- stimulated ultra-
arge vonWillebrand factorin a dose-dependent manner
nd IL-6 inhibited ultralarge von Willebrand factor
leavage [27]. Another study reporting endothelial cells
s targets of alloreactive donor cytotoxic T lymphocytes
as suggested that host endothelium may be another
arget organ for GVHD, which may explain its associa-
ion with TMA [28]. We found no response of TAM in
he absence of control of GVHD, further supporting a
ole of GVHD in the pathophysiology.
TAM may occur with reduced intensity prepara-
ive regimens [29-32]. We did not observe a difference
n the risk of TAM with RIC compared with ablative
onditioning. However, most of our patients received
udarabine, which has been reported to cause apopto-
is of endothelial cells and to increase allogenicity of
ndothelial cell targets for CD8 T cells after HSCT
33]. Direct endothelial toxicity from ﬂudarabine might
ffset a possible beneﬁt of less intensive regimens.
We did not analyze whether higher blood trough
acrolimus levels were predisposing to development
f TAM due to our limited resources to collect 3-4
easurements of blood trough tacrolimus levels be-
ore a deﬁned index date for all 1219 patients of this
ohort. However, one might assume that our patients
ith TAM would not have higher levels of tacrolimus
ecause most of the diagnoses were within the ﬁrst
00 d when the patients were still followed at our
nstitution and their blood trough tacrolimus levels
ere monitored meticulously to keep it within the
or patients with no response to therapy compared with respondersorter fherapeutic range.
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B. Oran et al.476The management of calcineurin inhibitors (cyclo-
porine and tacrolimus) poses a therapeutic dilemma
n patients with TAM. These agents are important for
revention and treatment of GVHD, which may ﬂare
f these agents are discontinued. Many reports have
ecommended dose reduction or temporary discontin-
ation of cyclosporine after TAM [9,34]. There are no
stablished guidelines regarding dose adjustment of
acrolimus. In our study, we continued tacrolimus
ith dose adjustment to the lower therapeutic range,
nless progressive renal dysfunction or encephalopa-
hy occurred. Patients with supratherapeutic tacroli-
us levels at TAM diagnosis had similar response
utcome as patients with therapeutic drug levels. Our
esults suggest that tacrolimus may be continued after
he diagnosis of TAM, particularly if concomitant
nfections can be controlled.
All patients underwent therapeutic PE unless they
ere unable to tolerate the procedure. Sixty percent
esponded with resolution of the signs of microangi-
pathy, which is comparable to reported results with
diopathic thrombotic thrombocytopenic purpura
22]. This should be interpreted with caution. The use
f PE is controversial and assessment of its efﬁcacy in
his setting requires a controlled trial. We found PE
as generally effective in controlling the symptoms of
icroangiopathy. However, even with response of
AM, there was a high rate of mortality, mostly sec-
ndary to GVHD or progression of the underlying
alignancy.
Infections may have an important role in the
athophysiology of TAM after HSCT [24,35].
ransplant recipients typically have multiple epi-
odes of infection, which may include different
athogens, making analysis of the relation complex.
n our series, infection was present in 70% of pa-
ients at TAM diagnosis. Fungal infection, which
as a low response rate to appropriate treatment,
as the only negative predictor for response to
AM therapy. There was no documented response
f TAM without control of the associated infection
nd control of GVHD.
In conclusion, this study indicates that post-trans-
lantation TAM is a serious, life-threatening compli-
ation after allogeneic HSCT using tacrolimus-based
VHD prophylaxis. The cumulative incidence of re-
ponse to treatment including PE was 60% and re-
uired control of coexisting GVHD and infections.
ortality remains high even in responders, with
VHD or progression of the underlying malignancy
s the most common causes of death. This indicates
he importance of novel nontoxic strategies for better
ontrol of GVHD and infection, which may favorably
ffect the incidence of TAM and its response to treat-
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